Medtronic to acquire Contego Medical for $380 million

Medtronic (NYSE:MDT) plans to acquire Contego Medical, a private medical device firm, for $380 million, with potential additional payments. The deal, expected to close in Q3 FY2025, expands Medtronic's carotid and peripheral vascular treatments. Contego's Neuroguard and Excipio devices will join Medtronic's portfolio. The acquisition is expected to be minimally dilutive to earnings in FY2027-2028, then neutral to accretive.

Original reporting
Published Nov 16, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MDT
Bullish
high confidence
Mentioned
$MDT
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDTBullishHigh
01

Why it matters

The acquisition adds FDA‑cleared carotid and thrombectomy technologies, aligning with Medtronic's growth strategy.

02

Market read

A material M&A announcement for a large‑cap healthcare company, likely to influence its stock and sector peers.

03

What to watch

Potential regulatory review timelines and the actual cash availability for the transaction.

Relevance 9/10Novelty 9/10Timing: announcement today

Background

Medtronic (NYSE:MDT) is a leading global medical technology company expanding its vascular treatment portfolio.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic announced a $380 million acquisition of private Contego Medical, expanding its carotid and peripheral vascular portfolio.

Expected impact

likely modest upside as investors price in the strategic expansion and accretive potential

Evidence & confidence

Large‑cap M&A with clear financial impact and no immediate financing strain typically supports a bullish reaction.

Market effects

strengthens Medtronic's position in the vascular device market, potentially pressuring peers.

U.S. healthcare sector may see slight uplift from the strategic acquisition.

limited to medical device industry, no broad market effect.

Counterpoint

Deal could be seen as overpaying for a niche private firm, risking integration challenges.

Key entities

  • Medtronic plc

    US‑listed medical device manufacturer (NYSE:MDT).

  • Contego Medical

    Privately held developer of carotid artery disease and peripheral thrombectomy solutions.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.